Amplia Therapeutics Limited INNMF
0.06 USD 0.00 (+9.26%)
At closeNov 3, 2026, 4:00 PM EST
0.0575 Day range 0.0575
0.05 52-week range 0.27
- YTD
- -25.32%
- 1 year
- -26.25%
- Market cap
- 30.29M
- EPS (ttm)
- -0.01
- YTD return
- -25.32%
- 1-year return
- -26.25%
- Volume
- 20.00K
- Avg volume
- 20.09K
- Open
- 0.0575
- Previous close
- 0.054
- Day's range
- 0.0575 – 0.0575
- 52-week range
- 0.05 – 0.27
2Y -0.0830 (-60.58%)
News
Amplia Therapeutics partners with Lilly on lung cancer combination trial 
Amplia Signs Collaboration Agreement With Lilly, Evaluating Narmafotinib Plus Lilly's Kras G12C Inhibitor, Olomorasib, in Non-small Cell Lung Cancer 
Scientific Paper Detailing Preclinical Studies of Narmafotinib in Pancreatic Cancer Now Online 
Amplia Announces Publication of New FAK Inhibitor Patent Application 
Amplia Announces Appointment of Brett Carter to Board 
Amplia Announces Changes to Board's Leadership Roles 
Following Significant Advances at ASCO, Amplia Therapeutics Provides Letter to Shareholders Highlighting the Potential Opportunities for Combination with KRAS Inhibition in Pancreatic Cancer 
Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib 
Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study 
Accent Trial Mature Data Presented at International Conference
Your note
Sign in to keep a note on INNMF — it syncs with the Stock Master app.